Month: September 2026

NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) — Brookfield Corporation (NYSE: BN, TSX: BN) and Brookfield Asset Management (NYSE: BAM, TSX: BAM) today announced that they will host their Investor Day in New York on Thursday, September 17, 2026.

Brookfield Asset Management’s event will run from 12:45 to 2:45 p.m. (ET), followed by Brookfield Corporation’s from 3:00 to 5:00 p.m. (ET).

The live webcast, along with copies of the presentations, can be accessed at www.brookfield.com/investorday or through www.bn.brookfield.com and www.bam.brookfield.com.

Please register for the webcast at least 15 minutes before the event to ensure an optimal viewing experience. For those unable to view the event live, a replay will be available on each company’s website shortly after the event.

About Brookfield

Brookfield is a leading global investment firm with more than $1 trillion in assets under management. The firm owns and operates high-quality businesses and real assets that provide essential services and form the backbone of the global economy. Brookfield invests on behalf of institutions and individuals around the world across infrastructure, energy, private equity, real estate, and credit. With more than a century of operating experience and a global presence in over 50 countries, Brookfield deploys long-term capital to generate sustainable value for its clients and shareholders.

For more information about Brookfield Corporation, please visit our investor relations website at www.bn.brookfield.com or contact:

Media: Kerrie McHugh Tel: (212) 618-3469 Email: kerrie.mchugh@brookfield.com

Investor Relations: Katie Battaglia Tel: (416) 359-8544 Email: katie.battaglia@brookfield.com

For more information about Brookfield Asset Management, please visit our investor relations website at www.bam.brookfield.com or contact:

Media: Simon Maine Tel: (332) 298-0447 Email: simon.maine@brookfield.com

Investor Relations: Jason Fooks Tel: (212) 417-2442 Email: jason.fooks@brookfield.com

Sale would simplify Hain’s portfolio and create a focused North American business; Net proceeds from the transaction would be used to reduce debt

HOBOKEN, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) — As part of its ongoing strategic review, Hain Celestial announced today it has reached a definitive agreement to sell its International business to global private equity firm AURELIUS for an estimated $323 million in cash. Net proceeds from the transaction are expected to range between $305 million and $310 million. Upon closing of the transaction, the proceeds would be used to reduce the Company’s debt. The agreement reflects the Board of Directors’ continued work to advance the Company’s strategic review, evaluate available alternatives and pursue paths designed to maximize value for all stakeholders.

The sale will include the majority of Hain’s International business operations and is inclusive of brands such as Ella’s Kitchen^® baby and kids foods, Joya^® and Natumi^® plant-based beverages, Hartley’s^® jelly, as well as Linda McCartney^® Foods, Cully & Sully^®, Yorkshire Provender^®, and New Covent Garden^® soups, among others.

Alison Lewis, Hain Celestial’s President and CEO, said, “Completing the transaction announced today would advance our strategy to simplify our portfolio and enable us to focus our resources on further reducing the Company’s debt. The resulting North American business would feature leading brands in attractive categories with a more streamlined operating model and greater focus on core growth opportunities.”

The Company’s resulting portfolio of brands in North America will include Celestial Seasonings^® teas, The Greek Gods^® yogurt and Earth’s Best^® Organic across its flagship categories of tea, yogurt and baby & kids foods. The portfolio also includes Spectrum^® Organic cooking oils, MaraNatha^® nut butters and Imagine^® broths.

Lewis continued, “I want to recognize the incredible people behind our International brands and business. Their dedication, expertise and commitment over many years is greatly appreciated. They have built remarkable brands, which we are confident will thrive under the new ownership.”

Hain Celestial remains in discussions with its lenders regarding an amendment to its credit agreement to extend the maturity date beyond December 22, 2026. The transaction with AURELIUS is conditioned upon the Company securing this amendment and may be terminated by AURELIUS if the amendment is not obtained within 30 days of signing. While there can be no assurance that an amendment will be obtained, the Board believes that extending the maturity date and completing the transaction would be in the best interests of the Company and its stakeholders.

The Company continues to focus on simplifying the organization and executing a plan to align its cost structure with the scale of the future North American business. Hain has developed detailed cost reduction plans and is moving with urgency to deliver these actions. The Company expects to implement cost reduction actions generating approximately $16 million of annualized savings on a run rate basis as compared to fiscal 2026. The Board and management team remain focused on swiftly executing these actions, while continuing to evaluate and advance all available paths under the strategic review to maximize value for the benefit of all stakeholders.

The agreement with AURELIUS has been unanimously approved by the Company’s Board. The transaction is subject to closing conditions, including regulatory approvals and an amendment to the Company’s credit agreement as described above. Subject to satisfaction of those conditions, the transaction is expected to close in Hain Celestial’s fiscal second quarter ending December 31, 2026.

Goldman Sachs is serving as the Company’s financial advisor on the transaction, and DLA Piper’s London team is serving as legal counsel.

The Company will discuss the proposed transaction during its Q4 2026 earnings conference call later today.

About The Hain Celestial Group
Hain Celestial is a leading global health and wellness company whose purpose is to inspire healthier living for people, communities and the planet through better-for-you brands. For more than 30 years, Hain Celestial has intentionally focused on delivering nutrition and well-being that positively impacts today and tomorrow. Headquartered in Hoboken, N.J., Hain Celestial’s products across beverages, yogurt, baby/kids and meal preparation are marketed and sold around the world. Our leading brands include Celestial Seasonings^® teas, The Greek Gods^® yogurt, Earth’s Best^® Organic and Ella’s Kitchen^® baby and kids foods, Joya^® and Natumi^® plant-based beverages, Hartley’s^® jelly, as well as Cully & Sully^®, Yorkshire Provender^®, New Covent Garden^® soups, among others. For more information, visit www.hain.com and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward-looking statements. The words “believe,” “expect,” “anticipate,” “may,” “should,” “plan,” “intend,” “potential,” “will” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, among other things, our beliefs or expectations relating to our future performance, results of operations and financial condition, including statements about the Company’s plan to sell its International business; the expected timetable for completing the transaction; cost-cutting initiatives; the outcome of the Company’s discussions with its lenders; the Company’s ability to create stakeholder value; and the outcome of the Company’s strategic review.

Risks and uncertainties that may cause actual results to differ materially from forward-looking statements include our ability to satisfy the conditions to the closing of the contemplated transaction, which may include conditions outside of our control; the upcoming maturity of the credit agreement in December 2026 and our ability to secure an extension of the maturity date with our lenders, including that any such amendment requires the consent of all lenders and that the failure to obtain it within the required period would permit the purchaser to terminate the agreement; and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, our Annual Report on Form 10-K expected to be filed today and our other filings from time to time with the U.S. Securities and Exchange Commission.

We undertake no obligation to update forward-looking statements to reflect actual results or changes in assumptions or circumstances, except as required by applicable law.

Media Contact:
Justin Godley
Justin.Godley@hain.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/585b1980-35bb-4dc4-aac1-be9029044b19

• Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer).
• Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatment-related change in adults and pediatric patients.
• FET-PET imaging is recommended in international clinical practice guidelines, including NCCN Guidelines®.
• Pixclara expands Telix’s industry-leading Precision Medicine business and reinforces the Company’s leadership in diagnostics and targeted radiopharmaceutical therapies (together, “theranostics”).

MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or ¹⁸F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer).

Pixclara is a radioactive diagnostic drug indicated for use with positron emission tomography (PET) to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older.

PET imaging with floretyrosine F 18 (FET-PET) is recommended in international clinical practice guidelines for the imaging of gliomas, including NCCN Guidelines®¹, but until now there has not been an FDA-approved product available in the U.S.

Gliomas are the most common form of central nervous system (CNS) cancer, accounting for approximately 30% of all brain and CNS tumors and 80% of all malignant brain tumors². In the U.S., approximately 24,000 new glioma cases are diagnosed each year³, representing a significant unmet addressable need.

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, said, “FDA approval of Pixclara will enable broad access in the U.S. to FET-PET imaging, which is already recognized in international clinical practice guidelines. As the first FDA-approved PET imaging drug for glioma, Pixclara will provide physicians in the U.S. with more certainty in their diagnoses and greater confidence in their treatment planning for patients.”

Kelly Sitkin, President and CEO, American Brain Tumor Association, said, “The approval of Pixclara will advance glioma care by enabling more precise monitoring, complementing the role of MRI. We welcome the FDA’s decision, which provides a pathway to access this technology in the U.S. and helps address a critical unmet need in brain cancer diagnostics.”

Patrick Wen, MD, E. Antonio Chiocca, MD, PhD, Family Endowed Chair in Neuro-Oncology at Mass General Brigham Cancer Institute, said, “Having an FDA-approved FET-PET product with high diagnostic accuracy will make a significant, positive difference to the management of patients with gliomas. This is a very positive step forward for brain cancer imaging and treatment planning.”

About Pixclara (floretyrosine F 18)

Pixclara® is an intravenous positron emission tomography (PET) imaging drug for the differentiation of recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older. It comprises a small molecule targeting compound labeled with a diagnostic radioisotope, fluorine-18. After administration into the bloodstream, Pixclara targets membrane transport proteins known as L-type amino acid transporters 1 and 2 (LAT1 and LAT2). Once bound, energy emissions from the radioisotope can be detected by a PET scanner. Pixclara (TLX101-Px) is also the subject of a Phase 3 registrational study for potential indication expansion for the diagnosis of brain metastases⁴.

Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer).

INDICATIONS AND USAGE 
PIXCLARA is indicated for use with positron emission tomography (PET) to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS
Risk for Misinterpretation
Image misinterpretation may occur with PIXCLARA PET. A negative image does not rule out the presence of recurrent or progressive glioma and a positive image does not confirm the presence of recurrent or progressive glioma. Equivocal findings may occur with PIXCLARA PET, including low-level or atypical uptake patterns, which may result in false positive or false negative interpretations.

Interpret PIXCLARA PET findings with caution and correlate results with available clinical evaluations, such as histopathology, cross-sectional imaging, and/or clinical history to support appropriate clinical decision-making.

Radiation Risks
PIXCLARA contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe drug handling to protect patients and health care providers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration.

ADVERSE REACTIONS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of PIXCLARA was evaluated in 382 patients with gliomas. Among these 382 patients, 371 adult patients received at least one intravenous dose of PIXCLARA at a mean activity of 204 ± 18 MBq (5.5 ± 0.47 mCi). The remaining 11 pediatric patients received at least one intravenous dose of PIXCLARA at a mean activity of 155 ± 53.5 MBq (4.2 ± 1.4 mCi).

The mean age of the patients was 57 years (range: 5 years to 86 years). Sex was 59% male, 37% female, and 3% unreported. Distribution by race was 26% White, 6% Asian, <1% Black or African American, and 67% other or unreported. Distribution by ethnicity was 3% Hispanic/Latino, 96% non-Hispanic/Latino, and <1% unknown or unreported.

Adverse reactions that occurred in ≥0.5% of patients receiving PIXCLARA were headache (0.5%).

Adverse reactions that occurred in <0.5% of patients were nausea, injection site reaction, fatigue, and malaise.

Adverse Reactions in Pediatric Patients

Overall, the safety profile observed in pediatric patients from the clinical study was consistent with the safety profile in adult patients.

Please note that this information is not comprehensive.
Please see the Full Prescribing Information at https://telixpharma.com/pixclara-uspi

You are encouraged to report suspected adverse reactions of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report adverse reactions to Telix Pharmaceuticals (US) by calling 1-844-455-8638 or emailing pharmacovigilance@telixpharma.com.

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease.

Telix’s commercial franchise is anchored by its precision diagnostics portfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S., and Gozellix® (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. Food and Drug Administration (FDA) for prostate imaging, and Pixclara® (floretyrosine F18) approved by the FDA for glioma imaging. The Company’s late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177 (¹⁷⁷Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (¹³¹I-iodofalan) in recurrent glioblastoma, and TLX250-Tx (lutetium (¹⁷⁷Lu) girentuximab tetraxetan) in kidney cancer, additionally complemented by a deep pipeline of next generation candidates. TLX591-Tx, TLX101-Tx and TLX250-Tx have not received marketing authorizations in any jurisdiction.

Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook.

Investor Relations Annie Kasparian annie.kasparian@telixpharma.com Charlene Jaw charlene.jaw@telixpharma.com	Media Eliza Schleifstein 917.763.8106 (Mobile) eliza@schleifsteinpr.com

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

___________________
¹ Galldiks et al. Lancet Oncol. 2025 (Joint guidelines from the European Association of Nuclear Medicine (EANM), European Association of Neuro-Oncology (EANO), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Response Assessment in Neuro-Oncology (RANO), The European Society for Pediatric Oncology and The Response Assessment in Pediatric Neuro-Oncology for the characterization of recurrence in glioma patients); National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers V3.2026.
² Goodenberger et al. Cancer Genet. 2012.
³ CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2018-2022. Neuro-Oncology. 2025.
⁴ Investigational New Drug (IND) application successfully cleared, with Study May Proceed notification received from FDA. Telix ASX disclosure August 20, 2026.

Key Takeaways:

• Parsons secured nine “Awardable” designations across two leading Department of War digital marketplaces designed to rapidly deploy operational capabilities to warfighters at the edge.
• Three solutions were recognized in Platform One and six in Tradewinds, expanding Parsons’ presence across the defense technology ecosystem.
• The designations enable faster evaluation, procurement, and deployment of innovative mission-focused capabilities.

CHANTILLY, Va., Sept. 14, 2026 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) announced today that nine of its digital solutions have been designated as “Awardable” across leading Department of War (DoW) digital marketplaces, accelerating government access to proven, mission-ready technologies.

For decades, Parsons has delivered innovative, rapid solutions to national security challenges that face the United States and its allies.

“Having nine Parsons solutions designated as ‘Awardable’ demonstrates the depth and maturity of our mission-ready defense product portfolio and reinforces our ability to deliver innovative capabilities that address our customers’ most critical national security challenges,” said Aaron Wajsgras, vice president of product strategy & commercialization for Parsons. “This achievement validates the mission impact of our products while meeting the Department of War’s mission requirements of faster and easier acquisition and deployment in support of critical national security priorities.”

Tradewinds Solutions Marketplace

Six Parsons solutions are designated “Awardable” in the Tradewinds Solutions Marketplace, a Department of War marketplace designed to accelerate the procurement and adoption of innovative commercial technologies through streamlined acquisition pathways. Parsons’ awardable solutions on Tradewinds include Ground Operations Command as a Service (GOCaaS), OrbitXchange™, SPARTAN Antenna, DroneArmor™, C2Core® Air, and Assured Positioning System (APS™).

• GOCaaS is a cloud-native satellite operations platform that provides automated commanding, telemetry analysis, orbit determination, maneuver planning, mission data delivery, and constellation management for any satellite, in any orbit, and any constellation size.
• OrbitXchange™ is an automated, cloud-native, cybersecure satellite communications solution that leverages commercial antenna networks to provide flexible, scalable, automated, and operationally proven ground station access.
• SPARTAN Antenna is an advanced phased-array-fed parabolic antenna system that enables simultaneous satellite commanding, telemetry, and mission data collection for up to eight spacecraft simultaneously through electronically steerable beams.
• DroneArmor™ is a fully automated counter-unmanned aircraft system (C-UAS) command-and-control platform that integrates sensors, effectors, and AI-enabled software to provide real-time drone threat detection, tracking, and response capabilities.
• C2Core® Air is a cloud-native command and control solution that enables end-to-end air operations planning, tasking, execution monitoring, and combat assessment within a distributed operating environment. Using the Strategy through Assessment workflow developed for C2Core, C2Core Air provides seamless integration of strategic, operational, and tactical levels of planning and mission management.
• APS™ provides resilient positioning, navigation, and timing (PNT) information when GPS or other global navigation satellite systems (GNSS) are jammed, spoofed, or otherwise unavailable or unreliable. APS uses proprietary satellite-based hybrid technology to produce reliable PNT data from non-GPS/non-GNSS RF transmissions from commercial and non-commercial communications satellites, including low-Earth orbit (LEO) vehicles. With APS, critical terrestrial and airborne applications that rely on PNT can continue to operate and execute their missions when GPS is undependable or unavailable.

The inclusion of these products in the Tradewinds Solutions Marketplace makes it easier for defense customers to rapidly identify, evaluate, and acquire trusted technologies that address evolving mission requirements.

Platform One Solutions Marketplace

Three Parsons solutions are designated “Awardable” in the Platform One Solutions Marketplace, one of DoW’s premier technology environments for discovering, evaluating, and rapidly acquiring vetted software capabilities. Sponsored by the U.S. Air Force, Platform One features post-competition solutions that enable organizations to identify and field mission-ready technologies. Parsons’ awardable solutions on Platform One include its Modern Extract, Transform, and Load (METAL) software application development approach, Support Velocity Helpdesk Automation solution, and TReX signal and channel emulation solution.

• METAL is a modern application development approach designed to handle large and complex data workloads, integrate diverse data sources, and provide resilient, scalable architectures using containerization, microservices, and Kubernetes.
• Support Velocity is an information technology service management (ITSM) solution that uses artificial intelligence (AI) and machine learning (ML) to categorize help desk tickets, reducing technician workload and improving resolution times.
• TReX is a software- and commercial off-the-shelf hardware-based signal and channel emulation solution that enables realistic electronic warfare testing, evaluation, and warfighter training using representative signals of interest.

The availability of these products on the Platform One Solutions Marketplace enables defense customers to rapidly identify, evaluate, and acquire mission-ready software and technology solutions.

For more information about Parsons awardable solutions on the defense marketplace, visit: Awardable Defense Marketplace Solutions | Parsons Corporation

About Parsons:
Parsons (NYSE: PSN) is a leading disruptive technology provider in the national security and global infrastructure markets, with capabilities across cyber and electronic warfare, space and missile defense, transportation, water and environment, urban development, and critical infrastructure protection. Please visit Parsons.com and follow us on LinkedIn to learn how we’re making an impact.

Forward-Looking Statements:
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on our current expectations, beliefs and assumptions, and are not guarantees of future performance. Forward-looking statements are inherently subject to uncertainties, risks, changes in circumstances, trends and factors that are difficult to predict, many of which are outside of our control. Accordingly, actual performance, results and events may vary materially from those indicated in the forward-looking statements, and you should not rely on the forward-looking statements as predictions of future performance, results or events. Numerous factors could cause actual future performance, results and events to differ materially from those indicated in the forward-looking statements, including, among others: any issue that compromises our relationships with the U.S. federal government or its agencies or other state, local or foreign governments or agencies; any issues that damage our professional reputation; changes in governmental priorities that shift expenditures away from agencies or programs that we support; our dependence on long-term government contracts, which are subject to the government’s budgetary approval process; the size of our addressable markets and the amount of government spending on private contractors; failure by us or our employees to obtain and maintain necessary security clearances or certifications; failure to comply with numerous laws and regulations; changes in government procurement, contract or other practices or the adoption by governments of new laws, rules, regulations and programs in a manner adverse to us; the termination or nonrenewal of our government contracts, particularly our contracts with the U.S. federal government; our ability to compete effectively in the competitive bidding process and delays, contract terminations or cancellations caused by competitors’ protests of major contract awards received by us; our ability to generate revenue under certain of our contracts; any inability to attract, train or retain employees with the requisite skills, experience and security clearances; the loss of members of senior management or failure to develop new leaders; misconduct or other improper activities from our employees or subcontractors; our ability to realize the full value of our backlog and the timing of our receipt of revenue under contracts included in backlog; changes in the mix of our contracts and our ability to accurately estimate or otherwise recover expenses, time and resources for our contracts; changes in estimates used in recognizing revenue; internal system or service failures and security breaches; and inherent uncertainties and potential adverse developments in legal proceedings, including litigation, audits, reviews and investigations, which may result in materially adverse judgments, settlements or other unfavorable outcomes. These factors are not exhaustive and additional factors could adversely affect our business and financial performance. For a discussion of additional factors that could materially adversely affect our business and financial performance, see the factors included under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and our other filings with the Securities and Exchange Commission. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. We assume no obligation to update any forward-looking statement made in this press release that becomes untrue because of subsequent events, new information or otherwise, except to the extent we are required to do so by law.

Media Contact:                                        
Bernadette Miller
+1 980.253.9781
bernadette.miller@parsons.com

Investor Relations Contact:
Dave Spille
+1 703.775.6191
Dave.Spille@parsons.us

Enhanced rail-pressure control, improved durability and more adaptable architecture deliver greater performance and integration flexibility, strengthening the case for broader adoption by OEMs and operators worldwide

VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) — Westport Fuel Systems Inc. (“Westport”) (TSX:WPRT / Nasdaq: WPRT), today announced Cespira, its joint venture with Volvo Group, released new technical details of HPDI™ 3.0, the next generation of its proven High Pressure Direct Injection fuel system.

HPDI 3.0 retains proven HPDI combustion principles while advancing fuel rail-pressure control, hardware durability and system integration. The new fuel system supports liquefied natural gas (LNG) and renewable bio-based liquefied natural gas (bioLNG) today while preserving adaptability for future low- and zero-carbon fuels.

Performance Enhancements
At its core, HPDI 3.0 incorporates a new fuel rail-pressure control architecture that improves fuel economy and engine performance while simplifying OEM calibration. Higher injection pressure capability unlocks greater power and efficiency from the latest high-performance compression-ignition engines, while the architecture is designed to support compliance with future global emissions regulations.

Improved Durability and Greater Integration Flexibility
The new hardware integrates proven HPDI injector dynamic sealing technology to enhance component service life. A modular fuel rail-pressure control architecture gives OEMs greater packaging flexibility across different engine layouts. The new system supports larger engines, including V12 and other multi-bank configurations, by allowing fuel pressure control across separate cylinder banks. This broadens the potential application of HPDI 3.0 across demanding on-road and off-road sectors.

Built for Natural Gas and Biogas Today, Adaptable for Future Fuels
HPDI 3.0 reinforces the near-term value of natural gas and renewable natural gas for heavy-duty transport by enabling the use of LNG and bioLNG with diesel-like performance, improved efficiency and attractive total cost of ownership. The architecture also maintains a clear pathway for future fuel-specific applications, including hydrogen, as those markets develop.

“Cespira’s revenue increased 125% year over year from Q2 2025 to Q2 2026, underscoring strong market validation for HPDI technology. With continued gains in efficiency, attractive total cost of ownership and improved fuel price stability, we believe HPDI is well positioned to grow adoption momentum with OEMs and fleets,” said Dan Sceli, Chief Executive Officer of Westport.

“HPDI 3.0 strengthens both the immediate and long-term business case for OEMs. More precise fuel rail pressure control, higher injection pressure capability, enhanced durability and improved fuel economy make HPDI 3.0 a more compelling proposition for LNG and BioLNG applications. The architecture is also more readily adaptable to future fuel-specific systems for hydrogen and low-carbon fuels, giving OEMs greater flexibility to build on their HPDI investment and expand their product portfolios as those fuel markets develop,” said Scott Baker, CTO of Cespira.

HPDI 3.0 builds on a proven technology foundation, with the current generation accumulating more than 3 billion kilometers of real-world operation across 12,000+ trucks in over 35 countries. Cespira will begin production of HPDI 3.0 in the fourth quarter of 2026, with the first HPDI 3.0 equipped vehicles expected on the road in early 2027.

More information about Cespira can be found at www.Cespira.com.

About Westport

Westport is a technology and innovation company connecting synergistic technologies to power a cleaner tomorrow. As a leading supplier of affordable, alternative fuel, low-emissions transportation technologies, we design, manufacture, and supply advanced components and systems that enable the transition from traditional fuels to cleaner energy solutions.

Our proven technologies support a wide range of alternative fuels – including natural gas, renewable natural gas, and hydrogen – empowering OEMs and commercial transportation industries to meet performance demands, regulatory requirements, and climate targets in a cost-effective way. With decades of expertise and a commitment to engineering excellence, Westport is helping our partners achieve sustainability goals-without compromising performance or cost-efficiency – making clean, scalable transport solutions a reality.

Westport is headquartered in Vancouver, Canada.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding, among other things, the anticipated performance, efficiency and emissions characteristics of Cespira’s HPDI™3.0 fuel system; the timing for commencement of production for HPDI 3.0 equipped vehicles and for such vehicles to be in operation; and the intentions, plans and actions of our joint venture and other partners. Forward-looking statements are based on management’s current expectations and assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. These risks, uncertainties and assumptions include, among others: the ability of Westport, Cespira and their partners to successfully develop, integrate, validate, and certify HPDI technology on expected timelines or at all; the results of testing and development activities and the ability to achieve required performance, durability, reliability, safety and regulatory requirements; the receipt and timing of required regulatory approvals, certifications and homologation, changes in laws, regulations and standards and incentive programs applicable to emissions, engine certification and vehicle classification; competitive technologies and products; general economic and market conditions; as well as other risk factors, uncertainties and assumptions that may affect our actual results, performance, achievements or financial position discussed in our most recent Annual Information Form and other filings with securities regulators. Readers should not place undue reliance on any such forward-looking statements, which speak only as of the date they were made. We disclaim any obligation to publicly update or revise such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in these forward looking statements except as required by National Instrument 51-102. The contents of any website, RSS feed or twitter account referenced in this press release are not incorporated by reference herein.

Contact Information
Westport Investor Relations
T: +1 604-718-2046

TORONTO, Sept. 14, 2026 (GLOBE NEWSWIRE) — TRX Gold Corporation (TSX: TRX) (NYSE American: TRX) (the “Company” or “TRX Gold”) is pleased to report that the Company has been added to the MVIS^® Global Junior Gold Miners Index (“MVGDXJ”) following the Q3 2026 index rebalance announcement on September 11, 2026.

Stephen Mullowney, TRX Gold CEO commented: “Following our addition to the S&P/TSX Global Mining Index announced on March 28, I am very pleased to announce that TRX Gold has now also met the criteria for inclusion in the MVGDXJ, which is designed to track the overall performance of small-capitalization companies that are involved primarily in the mining of gold and/or silver¹. TRX Gold’s inclusion in this major index has the potential to maintain and attract additional global institutional investment into the Company and increase liquidity, with the MVGDXJ being an important benchmark requirement for many large investment funds. This addition also positions the Company for possible inclusion in related funds and ETFs, including the Van Eck Junior Gold Miners ETF (“GDXJ^®”) which seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVGDXJ. Congratulations to the entire team on achieving this important milestone!”

For the MVIS Global Junior Gold Miners Index (MVGDXJ), the Q3 2026 rebalance schedule is as follows:

• Index data / reference date: August 31, 2026
• Rebalance announcement: September 11, 2026
• Index Implementation / rebalance date: September 18, 2026
• New composition becomes effective: September 21, 2026, the next trading day after implementation.

About MVGDXJ¹
The MVIS^® Global Junior Gold Miners Index (MVGDXJ) tracks the performance of the most liquid small-cap companies in the global gold and silver mining industries. This is a modified market cap-weighted index, and only includes companies that generate at least 50% of their revenue from gold or silver mining, or at least 50% of their mining mineral resources are from gold or silver. For more information about the MVIS^® Global Junior Gold Miners Index, please visit the index provider’s website.

¹Source: https://www.marketvector.com/indexes/hard-asset/mvis-global-junior-gold-miners

About TRX Gold Corporation

TRX Gold is a high margin and growing gold company advancing the Buckreef Gold Project in Tanzania. Buckreef Gold includes an established open pit operation and 2,000 tonnes per day process plant with upside potential demonstrated in the May 2025 Preliminary Economic Assessment (the “PEA”). The PEA outlines average gold production of 62,000 oz per annum over 17.6 years at 3,000 tonnes per day of throughput capacity, and a US$1.9 –US$2.6 billion pre-tax NPV_5% at average life of mine gold prices of US$4,000-US$5,000/oz. The Buckreef Gold Project hosts a Measured and Indicated Mineral Resource of 10.8 million tonnes (“MT”) at 2.57 grams per tonne (“g/t”) gold containing 893,000 ounces (“oz”) of gold and an Inferred Mineral Resource of 9.1 MT at 2.47 g/t gold for 726,000 oz of gold. The leadership team is focused on creating both near-term and long-term shareholder value by increasing gold production to generate positive cash flow to fund the expansion as outlined in the PEA and grow Mineral Resources through exploration. TRX Gold’s actions are led by the highest environmental, social and corporate governance (“ESG”) standards, evidenced by the relationships and programs that the Company has developed during its nearly two decades of presence in the Geita Region, Tanzania.

Qualified Person

Mr. Richard Boffey, BE Mining (Hons) F AusIMM, Chief Operating Officer of TRX Gold Corporation, is the Company’s in-house Qualified Person under National Instrument 43-101 “Standards of Disclosure for Mineral Projects” (“NI 43-101”) and has reviewed and assumes responsibility for the scientific and technical content in this press release.

For investor or shareholder inquiries, please contact:

Investor Relations
IR@TRXgold.com
+1-437-224-5241
+1 844 GOLD TRX (844-465-3879)
www.TRXgold.com

Forward-Looking and Cautionary Statements

This press release contains certain forward-looking statements as defined in the applicable securities laws. All statements, other than statements of historical facts, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “hopes”, “intends”, “estimated”, “potential”, “possible” and similar expressions, or statements that events, conditions or results “will”, “may”, “could” or “should” occur or be achieved. Forward-looking statements relate to future events or future performance and reflect TRX Gold management’s expectations or beliefs regarding future events and include, but are not limited to, statements with respect to future inclusion of TRX Gold in additional indices or funds, ability to attract investors or increase liquidity as a result of being included in any index or for any other reason, future gold prices, continued operating cash flow, expansion of its process plant, estimation of mineral resources, ability to develop value creating activities, recoveries, subsequent project testing, success, scope and viability of mining operations, the timing and amount of estimated future production and capital expenditures.

Although TRX Gold believes the expectations expressed in such forward-looking statements and the preliminary data included in this press release are based on reasonable assumptions, such statements are not guarantees of future performance. The actual achievements of TRX Gold or other future events or conditions may differ materially from those reflected in the preliminary data and forward-looking statements due to a variety of risks, uncertainties and other factors. These risks, uncertainties and factors include general business, legal, economic, competitive, political, regulatory and social uncertainties; actual results from operations, exploration activities and economic evaluations; fluctuations in currency exchange rates; changes in costs; future prices of gold and other minerals; mining method, production profile and mine plan; delays in exploration, development and construction activities; changes in government legislation and regulation; the ability to obtain financing on acceptable terms and in a timely manner or at all; contests over title to properties; employee relations and shortages of skilled personnel and contractors; the speculative nature of, and the risks involved in, the exploration, development and mining business. These risks are set forth in reports that TRX Gold files with the SEC and the various Canadian securities authorities. You can review and obtain copies of these filings from the SEC’s website at http://www.sec.gov/edgar.shtml and the Company’s profile on the System for Electronic Document Analysis and Retrieval (“SEDAR+”) at www.sedarplus.ca.

The disclosure contained in this press release of a scientific or technical nature relating to the Company’s Buckreef Project has been summarized or extracted from the technical report prepared in accordance with NI 43-101 – Standards of Disclosure for Mineral Projects on the Buckreef Gold Project (“Buckreef Gold”) titled Preliminary Economic Assessment and Updated Mineral Resource Estimate of the Buckreef Gold Mine Project, Tanzania (“PEA”) with an effective date of April 15, 2025. The PEA was prepared in accordance with NI 43-101 guidelines by P&E Mining Consultants Inc. (“P&E”). Input to this PEA was also provided by D.E.N.M. Engineering Ltd. (“D.E.N.M.”). The information contained herein is subject to all of the assumptions, qualifications and procedures set out in, and is qualified in its entirety by reference to the full text of, the PEA and reference should be made to the full details of the PEA which has been filed with the applicable regulatory authorities and is available on the Company’s profile at www.sedarplus.ca.

The information contained in this press release is as of the date of the press release and TRX Gold assumes no duty to update such information.